Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 59651-0055
Product Overview
NDC 59651-0055 corresponds to Vacuna Covid-19 Moderna, 100 mcg. It is the Moderna mRNA-1273 vaccine for COVID-19, authorized for emergency use and fully approved in various regions. The vaccine has been pivotal in pandemic mitigation efforts, with widespread administration globally.
Current Market Status
The Moderna COVID-19 vaccine maintains a significant market position driven by vaccine mandates, government stockpiles, and booster campaigns. As of 2023, Moderna has supplied over 1 billion doses worldwide, including applications in the US, Europe, and Asia.
Supply and Demand Dynamics
- Supply: Moderna has ramped production capacity to over 2 billion doses annually, with capacity expansion ongoing through 2024.
- Demand: Government procurement remains high, with multiyear supply agreements in the US, EU, and Japan. The demand for booster doses sustains vaccination programs but is decreasing in some markets due to infection decline and vaccine fatigue.
Competitive Landscape
- Main competitors: Pfizer-Bfizer's BNT162b2, Johnson & Johnson's Janssen, and emerging vaccines such as Novavax.
- Market share: Moderna holds approximately 30% in the global COVID-19 vaccine market, with regional variations.
Regulatory and Policy Environment
- Several countries transitioned from emergency use authorization to full approval, affecting purchase agreements.
- Governments increasingly shift towards purchasing booster doses annually, influencing volume stability.
Market Projections
- 2023-2024 Global Sales: Estimated at $8-$10 billion annually across all markets.
- Long-term outlook: As the pandemic transitions to endemic status, annual sales are expected to decline to the $2-$4 billion range by 2025, driven by booster campaigns and seasonal vaccinations.
Price Trends
- 2021-2022: Average government procurement price ranged from $15 to $20 per dose.
- 2023: Due to supply stabilization and increased competition, prices have declined, averaging approximately $10 to $12 per dose in high-volume government contracts.
- Future pricing: As global demand stabilizes and manufacturing costs decrease, prices may fall further to approximately $8-$10 per dose.
Price Differentiation Factors
- Volume discounts: Larger purchase commitments attract lower per-dose prices.
- Regional policies: Pricing varies significantly across countries based on negotiation power and procurement strategies.
- Product modifications: The development of variant-specific boosters could influence pricing structures.
Key Considerations for Stakeholders
- Supply contracts: Long-term agreements may secure favorable pricing.
- Market saturation: Declining demand in mature markets could pressure prices downward.
- Vaccine landscape: Introduction of new vaccines or waning immunity could alter market shares and pricing.
Risks and Opportunities
Risks: Reduced demand as herd immunity develops, competition from newer or more cost-effective vaccines, and regulatory changes.
Opportunities: Expansion into booster and pediatric indications, patent life extensions via new formulations, and regional market growth in low-income countries through subsidies.
Key Takeaways
- NDC 59651-0055 (Moderna COVID-19 vaccine) maintains a substantial market share amid high global demand.
- Sales are projected to decline from current levels ($8-$10 billion annually) to $2-$4 billion by 2025 as the pandemic subsides.
- Prices are trending downward, averaging $10-$12 per dose in 2023, with further reductions possible.
- Long-term profitability depends on development of new indications, supply agreements, and market shifts toward endemic management.
FAQs
1. What is the current annual sales estimate for NDC 59651-0055?
Approximately $8-$10 billion globally for 2023.
2. How is the pricing of Moderna's COVID-19 vaccine evolving?
Prices are decreasing, now averaging $10-$12 per dose, influenced by competition and supply stability.
3. What factors could influence future market size?
Introduction of alternative vaccines, booster dose demand, and regional vaccination policies.
4. Which regions dominate Moderna's COVID-19 vaccine market?
The United States, European Union, and Japan lead demand, with ongoing expansion in low-income countries.
5. How might regulatory developments impact the market?
Full approvals may solidify demand; changes in vaccination schedules or approvals of new versions could alter market dynamics.
References
- IQVIA Institute. "The Global Use of Medicines in 2023."
- CDC. "Vaccine Data & Supply."
- Pharma Intelligence. "2023 COVID-19 Vaccine Market Outlook."
- ReportLinker. "Global COVID-19 Vaccine Market Size and Forecast."
- US FDA. "Moderna COVID-19 Vaccine Approvals."
